



NanoString Technologies
Investor Relations Department
530 Fairview Ave. North
Suite 2000
Seattle, WA 98109
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: NSTG

Last Trade:	8.47
Trade Time:	4:00 PM ET Jan 22, 2018
Change:	0.14 ↑ (+1.681%)
Day Range	8.33 - 8.57
52-Week Range	7.03 - 20.70
Volume	202,455

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applica... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 19, 2018*
[NanoString Reports Inducement Grant Under NASDAQ Listing Rules](#)
- Jan 16, 2018*
[NanoString Appoints Thomas Bailey as Chief Financial Officer](#)
- Jan 8, 2018*
[NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2017](#)
- Jan 4, 2018*
[NanoString and RikenGenesis Announce Partnership to Commercialize nCounter-Based Diagnostic Assays in Japan](#)
- Dec 7, 2017*
[NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)